A Novel Treatment for Metastatic Melanoma
NCT00758797 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7
Last updated 2021-12-03
Summary
A novel treatment for metastatic melanoma combining a laser and an immune-system stimulating cream.
Conditions
Interventions
- OTHER
-
Photoimmunotherapy
DIOMED laser + photosensitizing agent injected intralesionally and topical immuno-modulating cream
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Murad Alam, MD · Northwestern University
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-04-30
- Primary Completion
- 2012-10-31
- Completion
- 2012-10-31
Countries
- United States
Study Locations
More Related Trials
-
The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma
NCT04017897 ·Status: UNKNOWN ·Phase: PHASE2
-
Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy
NCT00897520 ·Status: COMPLETED
-
A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma
NCT05572463 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes
NCT03370861 ·Status: TERMINATED
-
Mohs and Immunofluorescence for Malignant Melanoma In Situ
NCT02306512 ·Status: WITHDRAWN ·Phase: NA
-
Clinical Research on the Treatments on Advanced Malignant Melanoma by Combining in Situ Immunotherapy and Laser Therapy
NCT02372708 ·Status: COMPLETED
-
Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma
NCT06767306 ·Status: RECRUITING ·Phase: PHASE2
-
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
NCT02506153 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma
NCT01264731 ·Status: COMPLETED ·Phase: PHASE1
-
Study of PI-88 in Patients With Advanced Melanoma
NCT00068172 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL
NCT00724061 ·Status: TERMINATED ·Phase: NA
-
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
NCT06940739 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)
NCT03407170 ·Status: TERMINATED ·Phase: PHASE2
-
Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma
NCT01359956 ·Status: COMPLETED ·Phase: PHASE3
-
Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma
NCT05867004 ·Status: RECRUITING
-
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
NCT02581930 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma
NCT03957551 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma
NCT00007969 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Use of Fiber-optic Probe for Non-invasive Diagnosis of Melanoma and Assessment of Impact of Ultraviolet (UV) Exposure on Skin
NCT01085396 ·Status: TERMINATED
-
SBRT as a Vaccination for Metastatic Melanoma
NCT04042506 ·Status: WITHDRAWN ·Phase: PHASE2
-
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
NCT02965716 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma
NCT02650492 ·Status: TERMINATED ·Phase: NA
-
A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients
NCT00849875 ·Status: TERMINATED ·Phase: PHASE2
-
Fotemustine in Treating Patients With Metastatic Melanoma
NCT00560118 ·Status: TERMINATED ·Phase: PHASE2
-
Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases
NCT03754140 ·Status: WITHDRAWN ·Phase: PHASE2